Skip to main content

Table 1 Identification and validation success rates of CSC markers in ovarian cancer

From: Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention

Putative CSC marker Putative CSCs identified CSCs validated Screened only (references) Screened and validated (references)
CD133+ 10 of 11 5 of 5 [25, 27, 2931] [28, 3235]*
ALDH+ 4 of 4 4 of 4   [25, 27, 28, 33]*
HSP+ 4 of 4 4 of 4   [31, 3638]
CD44+ 12 of 12 1 of 2 [2732, 36, 39] [33, 40]
CD117+ 7 of 11 1 of 2   [33, 40]
CD24+ 7 of 7 1 of 1 [25, 28, 31, 32, 36] [41]
CD24- 1 of 1 1 of 1   [30]
ABCG2+ 2 of 3 0 of 2 [30] [28, 38]
  1. This table is ranked from top to bottom by the most frequently validated ovarian CSC markers. CSC validation is classified as a demonstration of increased xenograft tumorigenicity in the respective studies. Most studies screened for multiple CSC markers, while only bringing a sub-set forward for validation. This table makes the distinction between markers that were ‘screened only’ and those that were ‘screened and validated’ in the respective studies.
  2. *[33] found that CD133+ and ALDH+ putative CSCs validated as CSCs in most but not all of the patients tested. In other patients there was no significant difference between CD133+ and CD133- or ALDH+ and ALDH- cells in tumorigenicity. Additionally, in a small sub-set of patients CD133- not CD133+ cells were identified as CSCs.